Evaluation of genes identified by microarray analysis in favorable neuroblastoma

Pediatric Surgery International

Volumn 25, Issue 11, 2009, Pages 931-937

  Kamei, Naomi ^a   Hiyama, Keiko ^b   Yamaoka, Hiroaki ^a   Kamimatsuse, Arata ^a   Onitake, Yoshiyuki ^a   Sueda, Taijiro ^a   Hiyama, Eiso ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Favorable; Microarray; Neuroblastoma; Outcome; Risk stratification

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 26A1; NUCLEAR RECEPTOR DAX 1;

ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DHRS3 GENE; DNA MICROARRAY; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INFANT; MICROARRAY ANALYSIS; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT OUTCOME; UPREGULATION;

CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 70350189975     PISSN: 01790358     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00383-009-2448-1     Document Type: Article

References (14)

1. GM Brodeur 2003 Neuroblastoma: biological insights into a clinical enigma Nat Rev Cancer 3 3 203 216 10.1038/nrc1014 12612655 1:CAS:528: DC%2BD3sXhsFGhtr0%3D (Pubitemid 37328872)
2. F Westermann M Schwab 2002 Genetic parameters of neuroblastomas Cancer Lett 184 2 127 147 10.1016/S0304-3835(02)00199-4 12127685 1:CAS:528: DC%2BD38XlsVKmuro%3D (Pubitemid 34804499)
3. E Hiyama K Hiyama M Nishiyama CP Reynolds JW Shay T Yokoyama 2003 Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity J Pediatr Surg 38 12 1730 1734 10.1016/j.jpedsurg.2003.08.042 14666454 (Pubitemid 37505399)
4. E Hiyama K Hiyama H Yamaoka T Sueda CP Reynolds T Yokoyama 2004 Expression profiling of favorable and unfavorable neuroblastomas Pediatr Surg Int 20 1 33 38 10.1007/s00383-003-1077-3 14691637 (Pubitemid 40590606)
5. Hiyama E, Hiyama K (2002) Clinical application of microarrays as a tool of understanding cancer biology. In: Cancro MP (ed) Recent Res Develop Cancer, vol 4. Transworld Research Network, Kerala, India, pp 675-692
6. J Takita M Ishii S Tsutsumi Y Tanaka K Kato Y Toyoda R Hanada K Yamamoto Y Hayashi H Aburatani 2004 Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma Genes Chromosomes Cancer 40 2 120 132 10.1002/gcc.20021 15101045 1:CAS:528:DC%2BD2cXks1yhurs%3D (Pubitemid 38579880)
7. M Komatsu K Hiyama K Tanimoto M Yunokawa K Otani M Ohtaki E Hiyama J Kigawa M Ohwada M Suzuki N Nagai Y Kudo M Nishiyama 2006 Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers Mol Cancer Ther 5 3 767 775 10.1158/1535-7163.MCT-05-0408 16546992 1:CAS:528:DC%2BD28Xitl2ksro%3D
8. K Hiyama K Otani M Ohtaki K Satoh T Kumazaki T Takahashi Y Mitsui Y Okazaki Y Hayashizaki H Omatsu T Noguchi K Tanimoto M Nishiyama 2005 Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells Int J Oncol 27 1 87 95 15942647 1:CAS:528:DC%2BD2MXmtlKitr4%3D
9. GM Brodeur RC Seeger A Barrett F Berthold RP Castleberry G D'Angio B De Bernardi AE Evans M Favrot AI Freeman, et al. 1988 International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma J Clin Oncol 6 12 1874 1881 3199170 1:STN:280:DyaL1M%2FmvVSktA%3D%3D
10. H Shimada IM Ambros LP Dehner J Hata VV Joshi B Roald DO Stram RB Gerbing JN Lukens KK Matthay RP Castleberry 1999 The International Neuroblastoma Pathology Classification (the Shimada system) Cancer 86 2 364 372 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7 10421273 1:STN:280:DyaK1MzkslKnsw%3D%3D (Pubitemid 29327594)
11. S Sawaguchi M Kaneko J Uchino T Takeda M Iwafuchi S Matsuyama H Takahashi, et al. 1990 Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Study Group of Japan Cancer 66 1879 1887 10.1002/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0. CO;2-L 2224784 1:STN:280:DyaK3M%2FivFSqsw%3D%3D
12. S Abu-Abed P Dolle D Metzger C Wood G MacLean P Chambon M Petkovich 2003 Developing with lethal RA levels: genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1 Development 130 7 1449 1459 10.1242/dev.00357 12588859 1:CAS:528:DC%2BD3sXislOku7o%3D (Pubitemid 36410790)
13. K Niederreither S Abu-Abed B Schuhbaur M Petkovich P Chambon P Dolle 2002 Genetic evidence that oxidative derivatives of retinoic acid are not involved in retinoid signaling during mouse development Nat Genet 31 1 84 88 11953746 1:CAS:528:DC%2BD38Xjt1KnsrY%3D
14. P De Marco E Merello S Mascelli A Raso A Santamaria C Ottaviano MG Calevo A Cama V Capra 2006 Mutational screening of the CYP26A1 gene in patients with caudal regression syndrome Birth Defects Res A Clin Mol Teratol 76 2 86 95 10.1002/bdra.20225 16463413 1:CAS:528:DC%2BD28XisVWqsbY%3D (Pubitemid 43375822)